Radionuclide Therapy Development Services

Radionuclide therapy utilizes radionuclides to specifically target brain tumor cells, destroying tumor tissue through the release of radiant energy. Alfa Cytology assists clients by developing novel radionuclide carriers and targeting technologies to enhance the precision and efficacy of radionuclide therapy while reducing damage to healthy tissue.

Introduction to Radionuclide Therapy for Brain Tumors

Radionuclide therapy combines radionuclides with specific carriers-such as antibodies, peptides, or nanoparticles-that allow for precise targeting and accumulation at the site of a brain tumor. The radionuclides decay by emitting alpha particles, beta particles, or electrons, which directly damage the DNA of brain tumor cells, inhibiting their proliferation and inducing apoptosis. Compared to conventional radiotherapy, radionuclide therapy offers higher specificity and lower systemic toxicity. It is particularly suitable for brain tumors that are difficult to surgically remove or are prone to recurrence, such as glioblastoma and metastatic brain tumors.

Fig 1. RIT in early brain metastases. (CORROYER-DULMONT A, et al., 2021)

Radiotherapy for Brain Tumors

By specifically targeting brain tumor cells and releasing radiant energy, radionuclides are able to accurately destroy tumor tissue and inhibit its growth while minimizing damage to the surrounding healthy brain tissue.

• External Beam Radiotherapy (EBRT)

Modern radiotherapy techniques (such as 3D-CRT, IMRT, IGRT, and VMAT) use advanced imaging data and radiation modulation technologies to more precisely focus radiation on the three-dimensional shape of the tumor, enhancing treatment accuracy and efficiency.

• Stereotactic Radiosurgery (SRS)

Advanced radiotherapy like Gamma Knife, CyberKnife, TrueBeam, and Proton Beam Therapy deliver precise, high-dose radiation to tumors while minimizing damage to healthy tissue.

• Brachytherapy (Internal Radiotherapy)

Involves implanting radioactive sources (seeds or catheters) directly into or near the tumor tissue, delivering high doses of radiation locally with minimal impact on surrounding healthy brain tissue.

• Radionuclide Therapy (Targeted Radiotherapy)

Radionuclide-labeled molecules and radioimmunotherapy use radioactive isotopes, either alone or linked to monoclonal antibodies, to precisely target and destroy cancer cells while minimizing damage to healthy tissue.

Radionuclide Therapy Development for Brain Tumors

Disclaimer: Alfa Cytology focuses on providing preclinical research service. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.

Our Services

Alfa Cytology has the expertise to provide advanced radiotherapy development services for brain tumors, utilizing cutting-edge techniques such as radionuclide-labeled molecules and radioimmunotherapy to precisely target cancer cells while minimizing damage to healthy tissue. Leveraging our strengths in innovative radioactive treatments, we offer clients highly effective and precise therapeutic solutions.

RDC Conjugation Service

Alfa Cytology provides comprehensive, one-stop radiotherapy solutions for brain tumors, offering advanced treatments such as radionuclide-labeled molecules and radioimmunotherapy to ensure precise and effective care. If you have any related needs, please feel free to contact us for professional consultation and customized solutions.

Reference

1. CORROYER-DULMONT A, JAUDET C, FRELIN A M, et al. Radioimmunotherapy for Brain Metastases: The Potential for Inflammation as a Target of Choice [J]. Frontiers in oncology, 2021, 11: 714514.